P/E ratio for Laboratorios Farmaceuticos Rovi (ROVI.MC)
P/E ratio as of April 2024 (TTM): 24.2
According to Laboratorios Farmaceuticos Rovi's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 24.1593. At the end of 2022 the company had a P/E ratio of 9.52.
P/E ratio history for Laboratorios Farmaceuticos Rovi from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 9.52 | -64.24% |
| 2021 | 26.6 | -22.61% |
| 2020 | 34.4 | -0.07% |
| 2019 | 34.4 | -29.43% |
| 2018 | 48.8 | 8.94% |
| 2017 | 44.8 | 92.06% |
| 2016 | 23.3 | -35.39% |
| 2015 | 36.1 | 69.35% |
| 2014 | 21.3 | -1.12% |
| 2013 | 21.5 | 88.68% |
| 2012 | 11.4 | -4.69% |
| 2011 | 12.0 | 22.76% |
| 2010 | 9.76 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.